Biotech Values

[ghmm]

PP:

rkrw,

That was my first red flag. I have no problem with the assertion it is a great drug for Wilson's. And if I thought it was the next Cerezyme I may even overlook Kanzer and invest BUT there are already treatments out there the cost in the 100's of dollars. OK so some patients may need better therapy but that is about 10% (who don't respond to other therapy) AND I believe Coprexa is only used to initially get copper levels down (weeks) so I think the percent of the 6000 prevalence they get and 200 incidence is very small. I think insurance would balk at charging 200-300k as some suggest when other therapies are in the 1-2k range. I think Kanzer knows this and that is why he has Coprexa being the next cure for everything from IPF to Alzheimer's.

PP talked about Coprexa for IPF BEFORE their only human study data which was an open-label Phase 2a with 23 patients oh and by the way the first 3 patients in the study dropped out because the dose wasn't tolerated (they adjusted it). I didn't see specifics about the patient entry criteria (just that they were refractory but aren't all true IPF patients?). The results were not too impressive especially for an open label study. I am not even convinced they have the proper dose much less meaningful efficacy and a satisfactory safety profile for long-term use. So I can't see how they think they are going directly into a registration study?

While I like InterMune/Pirfenidone I certainly don't think the best treatment is near. It appears IPF is becoming the next PAH (in investment purposes) even got all the PAH companies thinking of trying their drugs in IPF (Viagra study, Iloprost failed, Bosentan study even Remodulin talked about). I would invest in a company I thought had a good chance with a drug for IPF (and where that was a meaningful portion of the company so I won't buy PFE) I have PP in the bottom portion of the growing list.